CMS Ends Breakthrough Devices’ Medicare Fast Track

Today, 30 September 2026, is the last day an FDA Breakthrough Device designation by itself can open the door to CMS's easier route to extra Medicare payment. CMS's FY2027 hospital payment rule repeals the "alternative pathway" that let any breakthrough-designated device qualify for New Technology Add-on Payments or Transitional Pass-Through Payments without separately proving substantial clinical improvement over existing care. A device designated by the end of today, and later cleared or approved by FDA in time, keeps the old route grandfathered. Everything designated tomorrow does not.

What the alternative pathway did

Since 2020, FDA Breakthrough Device designation carried a reimbursement shortcut as well as a regulatory one: a device with the designation, or Qualified Infectious Disease Product status, could qualify for a Medicare New Technology Add-on Payment (inpatient, under the Hospital Inpatient Prospective Payment System) or a Transitional Pass-Through Payment (outpatient, under the Hospital Outpatient Prospective Payment System) without independently demonstrating substantial clinical improvement over existing care — one of the three tests every other new technology has always had to pass, alongside newness and cost. CMS's FY2027 IPPS/LTCH final rule, docket CMS-1849-F, finalized 31 July 2026 and published in the Federal Register 4 August 2026, repeals that exemption. Starting with FY2028 NTAP applications, and for OPPS pass-through applications filed on or after 1 October 2026, breakthrough-designated devices face the same substantial-clinical-improvement bar as everyone else.

The grandfather clause, and its own deadline

The rule preserves the old pathway for one cohort: a device that holds FDA Breakthrough Device designation as of today, 30 September 2026, and that later receives FDA marketing authorization for the covered indication by 1 May 2028, keeps access to the alternative pathway through the FY/CY2029 rulemaking cycle. That makes today a hard line on the front end — a designation granted tomorrow gets no grandfathering at all — and 1 May 2028 a second hard line on the back end, for sponsors who already hold designation but have not yet reached FDA authorization. STAT News reported 29 September 2026 that manufacturers have been racing to lock in designation ahead of today's cutoff, citing recent Breakthrough Device grants for triage algorithms reading abdominal CT scans, diagnostic panels for urinary tract infections, and thrombectomy robots as examples of the late push.

What CMS offers in its place

CMS and FDA rolled out a joint coverage pathway, RAPID (Regulatory Alignment for Predictable and Immediate Device review), on 23 April 2026 — intended to align FDA's premarket evidence review with Medicare coverage decisions and get some Breakthrough Devices to national coverage within 60 to 90 days of authorization. CMS has pointed to RAPID as the intended offset for the NTAP/TPT repeal: a faster path to coverage, in place of an easier path to extra payment. AdvaMed has publicly objected to the repeal itself, saying the alternative pathway “has worked well” and that rolling it back would be disappointing; some members of Congress have separately floated legislation to guarantee Medicare coverage for breakthrough technologies, according to earlier reporting.

Why it matters for regulatory strategy, not just reimbursement

Breakthrough Device designation decisions are made by regulatory affairs teams, often years before a product reaches the market — and until today, that designation carried a downstream reimbursement benefit that made it worth pursuing even when the clinical program alone might not have justified the effort. That link breaks starting tomorrow. Sponsors weighing whether to seek designation now need to build a substantial-clinical-improvement case into the premarket evidence plan from the outset, the same as any other new technology. Sponsors who already hold designation and are not yet through FDA authorization have a new deadline of their own: 1 May 2028, or the grandfathered payment benefit disappears regardless of when the designation was granted. Regulatory News was not able to independently verify the FY2027 NTAP dollar and technology-count figures cited by trade press against CMS's own fact sheet, and flags them as sourced to that reporting rather than confirmed directly.

Frequently asked questions

What ends today, 30 September 2026?

CMS's alternative Medicare add-on payment pathway, which let any FDA Breakthrough Device designation alone qualify a technology for extra payment without proving substantial clinical improvement. The repeal comes from CMS's FY2027 IPPS/LTCH final rule, effective 1 October 2026.

What is the grandfather clause?

A device designated by today that later wins FDA marketing authorization by 1 May 2028 keeps the old pathway through FY/CY2029. Designation after today gets no grandfathering; missing the 2028 authorization deadline forfeits it even for a timely designation.

What replaces the alternative pathway?

The traditional newness/cost/substantial-clinical-improvement test all technologies already face. CMS points to its joint FDA "RAPID" coverage pathway, launched 23 April 2026, as the intended offset, targeting national coverage within 60-90 days of FDA authorization for some Breakthrough Devices.

How big is the affected program?

Trade press citing CMS's FY2027 NTAP tally puts roughly $418 million in FY2027 payments across 16 alternative-pathway technologies, against about $481 million across 3 traditional-pathway approvals; Regulatory News has not independently verified these figures against CMS's own fact sheet.